Seeing Is Believing

Currently out of the existing stock ratings of Mani Foroohar, 121 are a BUY (53.54%), 89 are a HOLD (39.38%), 16 are a SELL (7.08%).
Analyst Mani Foroohar, currently employed at LEERINK, carries an average stock price target met ratio of 54.47% that have a potential upside of 40.43% achieved within 218 days.
Mani Foroohar’s has documented 422 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LXEO, Lexeo Therapeutics, Common Stock at 07-Oct-2025.
Analyst best performing recommendations are on FDMT (4D MOLECULAR THERAPEUTICS ).
The best stock recommendation documented was for FDMT (4D MOLECULAR THERAPEUTICS ) at 11/14/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.51 (11.19%) receiving and performance score of 111.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
1 months ago
(22-Sep-2025)
0/4 (0%)
$23.75 (380.00%)
Buy
2 months 10 days ago
(12-Aug-2025)
3/4 (75%)
$30.52 (321.94%)
884
Buy
$12
$7.71 (179.72%)
$16
3 months 28 days ago
(24-Jun-2025)
1/4 (25%)
$9.42 (365.12%)
292
Hold
$4
$-0.29 (-6.76%)
$5
5 months 8 days ago
(14-May-2025)
3/5 (60%)
$1.95 (95.12%)
127
Buy
$6
$4.05 (207.69%)
$4
2 years 1 months 18 days ago
(05-Sep-2023)
4/7 (57.14%)
$4.22 (237.08%)
196
Which stock is Mani Foroohar is most bullish on?
Which stock is Mani Foroohar is most reserved on?
What Year was the first public recommendation made by Mani Foroohar?